RS
CATX icon

R Squared’s Perspective Therapeutics CATX Stock Holding History

R Squared’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,991
Closed -$44K – 515
2025
Q4 		$44K Buy
+15,991
New +$45.6K 0.02% 467
2025
Q1 		– Sell
-4,100
Closed -$13.1K – 500
2024
Q4 		$13.1K Buy
+4,100
New +$33.5K 0.01% 1060

Other funds holding CATX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

R Squared's CATX Position: Q1 2026 in Review

R Squared sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 15,991 shares — an estimated $44K sold.

R Squared first reported a position in CATX in Q4 2024 and held it in 2 quarters. The position peaked at $44K in Q4 2025. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • R Squared reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • R Squared sold 15,991 Perspective Therapeutics shares in Q1 2026, an estimated $44K.
  • R Squared first reported a position in Perspective Therapeutics in Q4 2024 and held it in 2 quarters.
  • R Squared's Perspective Therapeutics position peaked at $44K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.